RE: its here7 Oct 2020 09:07
P values not as good as hoped - from the RNS
A summary of the results for the FAS (n=353) is given below, showing Blautix® achieved:
· In the IBS-C/D combined group (n=170), a statistically significant overall response rate of 24.1% compared to 17.5% for placebo (n=183) (p=0.0625), representing an RR of 1.38 (95% confidence interval: 0.913, 2.083);
· In IBS-C patients (n=76) a numerically superior but statistically non-significant overall response rates of 25% compared to 17.1% for placebo (n=82) (p=0.152), representing an RR of 1.46 (95% confidence interval: 0.791, 2.711); and
· In IBS-D patients (n=94) a numerically superior but statistically non-significant overall response rate of 23.4% compared to 17.8% for placebo (n=101) (p=0.216), representing an RR of 1.31 (95% confidence interval: 0.753, 2.290).
However considering how little treatments there are out there i'm not sure how the market will take this.